Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
22.04.2024 - Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (“ML”) platform with multiple clinical-stage drug programs, ... Seite 1
Source: wallstreet-online.de